* Some very early clinical data testing an anti-GD2 CAR-T with constitutive signaling from an engineered IL-7 receptor
Recent LYEL News
- Lyell Immunopharma Announces Participation in Goldman Sachs Cell Therapy Day • GlobeNewswire Inc. • 09/24/2024 08:05:00 PM
- Lyell Immunopharma Announces Participation in September Investor Conferences • GlobeNewswire Inc. • 08/28/2024 08:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/07/2024 08:06:44 PM
- Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2024 • GlobeNewswire Inc. • 08/07/2024 08:05:00 PM
- Lyell Immunopharma Reports Dose-dependent Clinical Activity from Phase 1 Trial of LYL797, a ROR1-targeted CAR-T Cell Product Candidate Enhanced with its Proprietary Anti-exhaustion Technology • GlobeNewswire Inc. • 06/26/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/14/2024 08:07:01 PM
- Lyell Immunopharma to Participate in the Goldman Sachs Global Healthcare Conference • GlobeNewswire Inc. • 06/03/2024 08:05:00 PM
- Lyell Immunopharma to Participate in BofA Securities Health Care Conference • GlobeNewswire Inc. • 05/07/2024 08:05:00 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 05/06/2024 12:12:11 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/06/2024 12:06:23 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/06/2024 12:03:04 PM
- Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2024 • GlobeNewswire Inc. • 05/06/2024 12:00:00 PM
- Lyell Immunopharma Announces the Acceptance of Three Abstracts for Presentation at 2024 AACR Annual Meeting • GlobeNewswire Inc. • 03/05/2024 09:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/28/2024 09:07:21 PM
- Lyell Immunopharma Reports Business Highlights and Financial Results for the Fourth Quarter and Full Year 2023 • GlobeNewswire Inc. • 02/28/2024 09:05:00 PM
- Lyell Immunopharma Announces Participation in March Investor Conferences • GlobeNewswire Inc. • 02/26/2024 09:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/14/2024 01:24:01 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/14/2024 01:22:01 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/14/2024 01:19:16 AM
- Lyell Immunopharma to Participate in 42nd Annual J.P. Morgan Healthcare Conference • GlobeNewswire Inc. • 01/03/2024 09:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/21/2023 01:55:59 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/21/2023 01:54:37 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/21/2023 01:52:09 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2023 09:26:02 PM
- Lyell Immunopharma Receives FDA Orphan Drug Designation for LYL845 for the Treatment of Melanoma • GlobeNewswire Inc. • 11/09/2023 09:05:00 PM
Lingerie Fighting Championships Signs Broadcast Deal With Maybacks Global Entertainment • BOTY • Sep 26, 2024 9:00 AM
Maybacks Global Entertainment and Lingerie Fighting Championships Enter Into Broadcast And Revenue Sharing Agreement • AHRO • Sep 26, 2024 8:30 AM
North Bay Resources Commences Operations at Bishop Gold Mill, Inyo County, California; Engages Sabean Group Management Consulting • NBRI • Sep 25, 2024 9:15 AM
CEO David B. Dorwart Anticipates a Bright Future at Good Gaming Inc. Through His Most Recent Shareholder Update • GMER • Sep 25, 2024 8:30 AM
Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • BLOZF • Sep 24, 2024 8:50 AM
Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • INTV • Sep 24, 2024 8:45 AM